BioCentury survey finds action lags concern about COVID-19's business impact
Biotech execs and investors express ample concern but take little action to avoid business disruptions from COVID-19
While biotech executives and investors are clearly worried about how COVID-19 will affect their businesses, a minority has done anything about it. Top of mind is disruption to clinical trials. The effect of an economic downturn on fund-raising is another big concern, though investors are more concerned for portfolio companies than themselves.
BioCentury conducted a survey of 73 biopharma executives and investors on the impact of the COVID-19 outbreak...